Rationale and design of the Dapagliflozin after Transcatheter Aortic Valve Implantation (DapaTAVI) randomized trial.

Ignacio J Amat-SantosJuan P Sánchez-LunaEmad Abu-AssiMaría Melendo-ViuIgnacio Cruz-GonzalezLuis Nombela-FrancoAntonio J Muñoz-GarcíSergio G BlasJose M de la Torre HernandezRafael RomagueraÁngel Sánchez-RecaldeJosé L Diez-GilDiego Lopez-OteroLivia GheorgeBorja IbáñezAndrés Iñiguez-RomoSergio Raposeiras-Roubinnull null

Published in: European journal of heart failure (2021)

DapaTAVI will determine the efficacy and safety of dapagliflozin in a broad spectrum of frail patients after AS relief by TAVI.

Keyphrases

transcatheter aortic valve implantation
aortic stenosis
ejection fraction
aortic valve
aortic valve replacement
end stage renal disease
chronic kidney disease
newly diagnosed
transcatheter aortic valve replacement
prognostic factors
left ventricular
atrial fibrillation
community dwelling